SCHEMBL20108827

SCHEMBL20108827

N#Cc1cccc(Cn2c(Cn3cc(-c4cccc(O)c4)c4c(N)ncnc43)nc3cccc(Br)c3c2=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 8/20 0.48
PIK3CG P48736 7/20 0.48
PIK3R1 P27986 3/20 0.48
SRC P12931 11/20 0.41
FGR P09769 1/20 0.41
EPHA1 P21709 1/20 0.41
TXK P42681 1/20 0.41
FRK P42685 1/20 0.41
PTK6 Q13882 1/20 0.41
ABL1 P00519 11/20 0.40
EGFR P00533 9/20 0.40
ABL2 P42684 8/20 0.40
LCK P06239 7/20 0.40
IGF1R P08069 4/20 0.40
JAK2 O60674 3/20 0.40
INSR P06213 3/20 0.40
RET P07949 3/20 0.40
KIT P10721 3/20 0.40
PDGFRA P16234 3/20 0.40
FGFR4 P22455 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11078 0.86 PIK3CD (0.66) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL11472 0.77 PIK3CD (0.79) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL31655791 0.77 PIK3CD (0.79) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL11928103 0.73 PIK3CD (0.61) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL10924 0.73 CFTR (0.47) PIK3R1PIK3CAMAPK14
SCHEMBL31655806 0.72 PIK3CD (0.69) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL11476 0.72 PIK3CD (0.69) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL31655803 0.71 PIK3CD (0.69) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL11831 0.71 PIK3CD (0.69) PIK3CDPIK3CGPIK3R1SRCABL1
SCHEMBL8581 0.69 PIK3CD (0.83) PIK3CDPIK3CGPIK3R1SRCABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180118754-A1 COMPOUNDS RESPIVERT LTD. (GB) 2018-05-03 US disclosed
US-20180118754-A1 COMPOUNDS RESPIVERT LTD. (GB) 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118754-A1 COMPOUNDS LTC4S, CYP11B2, LTB4R2 PIK3CD 4224/4885PIK3CG 3708/4885PIK3R1 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.